Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B?

Individualized HCC risk estimates can help clinicians stratify patients into high- and low-risk groups, enabling tailored surveillance strategies. However, the practical use of existing tools remains limited by the lack of wide validation, variability in access to laboratory testing, and the inability to accurately predict dynamic changes in HCC risk over time. For most patients with CHB, HCC risk remains sufficiently high enough to justify ongoing HCC surveillance. However, in select low-risk patients, surveillance may be delayed or stopped with regular reassessment of HCC risk and shared decision-making, given the limitations of existing tools and the likelihood of changes in HCC risk over time.